The ARRIVE trial (2018) evaluated elective induction at 39 weeks versus expectant management in low-risk nulliparous women. The key finding was that elective induction at 39 weeks:

• A Significantly reduced cesarean delivery rate ✓
• B Significantly increased cesarean delivery rate
• C Had no effect on cesarean rate but reduced perinatal mortality
• D Increased neonatal ICU admission rate

Explanation

Contrary to prior assumptions, the ARRIVE trial demonstrated that elective induction of labor at 39 weeks in low-risk nulliparous women was associated with a lower cesarean delivery rate (18.6% vs 22.2%) and lower rates of hypertensive disorders compared to expectant management. The trial challenged the traditional belief that induction increases cesarean risk and changed practice significantly.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.